286 related articles for article (PubMed ID: 26717395)
41. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
42. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.
Ruggeri G; Bandiera E; Zanotti L; Belloli S; Ravaggi A; Romani C; Bignotti E; Tassi RA; Tognon G; Galli C; Caimi L; Pecorelli S
Clin Chim Acta; 2011 Jul; 412(15-16):1447-53. PubMed ID: 21557935
[TBL] [Abstract][Full Text] [Related]
43. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
44. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
Gynecol Oncol; 2016 Oct; 143(1):128-134. PubMed ID: 27426308
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer.
Lee SS; Park JS; Lee KB; Jeong DH; Byun JM; Lee SM
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1123-1127. PubMed ID: 33906304
[TBL] [Abstract][Full Text] [Related]
47. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
48. Looking for optimized weights of CA125 and HE4 in early screening system of ovarian cancer for Korean patients.
Song HJ; Nam KM; Kim JD; Park CY; Kim YS
Technol Health Care; 2015; 24 Suppl 1():S163-70. PubMed ID: 26409552
[TBL] [Abstract][Full Text] [Related]
49. HE4 combined with CA125: favorable screening tool for ovarian cancer.
Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
[TBL] [Abstract][Full Text] [Related]
50. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
51. Value of the risk of ovarian malignancy algorithm index in predicting the recurrence of epithelial ovarian cancer.
Li R; Ma S; Zu Y; Wang F; Gao T; Yang Y; Guo H; Ha C
Biomark Med; 2022 Oct; 16(14):1055-1066. PubMed ID: 36062577
[No Abstract] [Full Text] [Related]
52. RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population-based study.
Liest AL; Omran AS; Mikiver R; Rosenberg P; Uppugunduri S
Acta Obstet Gynecol Scand; 2019 Jan; 98(1):24-33. PubMed ID: 30216407
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
[TBL] [Abstract][Full Text] [Related]
54. Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: A multicenter prospective study.
Shen F; Lu S; Peng Y; Yang F; Chen Y; Lin Y; Yang C; Wu L; Li H; Zheng Y
Clin Chim Acta; 2017 Aug; 471():119-125. PubMed ID: 28549533
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer.
Luo HJ; Hu ZD; Cui M; Zhang XF; Tian WY; Ma CQ; Ren YN; Dong ZL
J Obstet Gynaecol Res; 2023 Mar; 49(3):998-1006. PubMed ID: 36609691
[TBL] [Abstract][Full Text] [Related]
56. Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women.
Lu J; Zheng Z; Zhang Q; Li G; Li F; Le Z; Huang J; Xie X; Zhang J
J Clin Lab Anal; 2018 Jun; 32(5):e22368. PubMed ID: 29194801
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
58. The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-Müllerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer.
Hou X; Liu S; Liu J; Zhou J; Liang Y; Cui L
Clin Biochem; 2023 Sep; 119():110615. PubMed ID: 37517433
[TBL] [Abstract][Full Text] [Related]
59. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
60. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]